KALA BIO, Inc. (NASDAQ:KALA) Short Interest Up 19.1% in January

KALA BIO, Inc. (NASDAQ:KALA) was the recipient of a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 25,600 shares, an increase of 19.1% from the December 31st total of 21,500 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average trading volume of 34,800 shares, the days-to-cover ratio is currently 0.7 days.

KALA BIO Trading Down 3.0 %

Shares of NASDAQ:KALA traded down $0.28 during mid-day trading on Friday, hitting $9.20. The company had a trading volume of 188,055 shares, compared to its average volume of 57,641. The company has a market capitalization of $56.03 million, a PE ratio of -0.74 and a beta of -2.11. KALA BIO has a one year low of $4.21 and a one year high of $9.74. The firm has a fifty day moving average price of $7.01 and a 200 day moving average price of $6.45. The company has a debt-to-equity ratio of 3.18, a current ratio of 2.15 and a quick ratio of 2.15.

KALA BIO (NASDAQ:KALA) last issued its earnings results on Tuesday, November 12th. The company reported ($1.93) EPS for the quarter, beating the consensus estimate of ($2.43) by $0.50. As a group, research analysts forecast that KALA BIO will post -10.84 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of KALA BIO in a research report on Friday, November 15th.

Insider Buying and Selling at KALA BIO

In related news, CEO Mark T. Iwicki sold 5,779 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $7.63, for a total transaction of $44,093.77. Following the transaction, the chief executive officer now directly owns 280,076 shares in the company, valued at approximately $2,136,979.88. The trade was a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bros. Advisors Lp Baker purchased 310,559 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average price of $6.44 per share, for a total transaction of $1,999,999.96. Following the purchase, the insider now owns 1,083,398 shares in the company, valued at $6,977,083.12. This trade represents a 40.18 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 9,506 shares of company stock valued at $72,531. 8.32% of the stock is currently owned by insiders.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.